These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 25278492)

  • 1. Alpha synuclein is transported into and out of the brain by the blood-brain barrier.
    Sui YT; Bullock KM; Erickson MA; Zhang J; Banks WA
    Peptides; 2014 Dec; 62():197-202. PubMed ID: 25278492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease?
    Matsumoto J; Stewart T; Sheng L; Li N; Bullock K; Song N; Shi M; Banks WA; Zhang J
    Acta Neuropathol Commun; 2017 Sep; 5(1):71. PubMed ID: 28903781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.
    Spencer B; Trinh I; Rockenstein E; Mante M; Florio J; Adame A; El-Agnaf OMA; Kim C; Masliah E; Rissman RA
    Neurobiol Dis; 2019 Jul; 127():163-177. PubMed ID: 30849508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains.
    Longhena F; Faustini G; Varanita T; Zaltieri M; Porrini V; Tessari I; Poliani PL; Missale C; Borroni B; Padovani A; Bubacco L; Pizzi M; Spano P; Bellucci A
    Brain Pathol; 2018 Nov; 28(6):875-888. PubMed ID: 29330884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graphene quantum dots prevent α-synucleinopathy in Parkinson's disease.
    Kim D; Yoo JM; Hwang H; Lee J; Lee SH; Yun SP; Park MJ; Lee M; Choi S; Kwon SH; Lee S; Kwon SH; Kim S; Park YJ; Kinoshita M; Lee YH; Shin S; Paik SR; Lee SJ; Lee S; Hong BH; Ko HS
    Nat Nanotechnol; 2018 Sep; 13(9):812-818. PubMed ID: 29988049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
    Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.
    Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA
    J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Synuclein Interacts with Lipoproteins in Plasma.
    Emamzadeh FN; Allsop D
    J Mol Neurosci; 2017 Oct; 63(2):165-172. PubMed ID: 28887769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease.
    O'Hara DM; Kalia SK; Kalia LV
    Crit Rev Clin Lab Sci; 2020 Aug; 57(5):291-307. PubMed ID: 32116096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
    Wang R; Sun H; Ren H; Wang G
    Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interaction between alpha-synuclein and mitochondrial dysfunction in Parkinson's disease.
    Li HY; Liu DS; Zhang YB; Rong H; Zhang XJ
    Biophys Chem; 2023 Dec; 303():107122. PubMed ID: 37839353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson's disease in rodent brains.
    Bérard M; Martínez-Drudis L; Sheta R; El-Agnaf OMA; Oueslati A
    Mol Neurodegener; 2023 Nov; 18(1):91. PubMed ID: 38012703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuronal ApoE Regulates the Cell-to-Cell Transmission of α-Synuclein.
    Kang SJ; Kim SJ; Noh HR; Kim BJ; Kim JB; Jin U; Park SA; Park SM
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRP1 is a neuronal receptor for α-synuclein uptake and spread.
    Chen K; Martens YA; Meneses A; Ryu DH; Lu W; Raulin AC; Li F; Zhao J; Chen Y; Jin Y; Linares C; Goodwin M; Li Y; Liu CC; Kanekiyo T; Holtzman DM; Golde TE; Bu G; Zhao N
    Mol Neurodegener; 2022 Sep; 17(1):57. PubMed ID: 36056345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models.
    Liu Q; Hou J; Chen X; Liu G; Zhang D; Sun H; Zhang J
    PLoS One; 2014; 9(7):e102442. PubMed ID: 25036090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease.
    Kim KS; Choi YR; Park JY; Lee JH; Kim DK; Lee SJ; Paik SR; Jou I; Park SM
    J Biol Chem; 2012 Jul; 287(30):24862-72. PubMed ID: 22619171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structurally distinct α-synuclein fibrils induce robust parkinsonian pathology.
    Hayakawa H; Nakatani R; Ikenaka K; Aguirre C; Choong CJ; Tsuda H; Nagano S; Koike M; Ikeuchi T; Hasegawa M; Papa SM; Nagai Y; Mochizuki H; Baba K
    Mov Disord; 2020 Feb; 35(2):256-267. PubMed ID: 31643109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular events underlying the cell-to-cell transmission of α-synuclein.
    Choi YR; Park SJ; Park SM
    FEBS J; 2021 Dec; 288(23):6593-6602. PubMed ID: 33332736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.